<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00069316</url>
  </required_header>
  <id_info>
    <org_study_id>030306</org_study_id>
    <secondary_id>03-CC-0306</secondary_id>
    <nct_id>NCT00069316</nct_id>
  </id_info>
  <brief_title>Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease</brief_title>
  <official_title>A Phase I/II Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin G (Omr-IgG-am) Containing High Anti-West Nile Virus Antibody Titers in Patients With, or at High Risk for Progression to West Nile Virus(WNV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Investigators will assess whether Omr-IgG-am(Trademark), an intravenous immunoglobulin (IVIg)
      containing antibodies specific for West Nile virus (WNV), is safe and well-tolerated in
      patients with suspected or laboratory diagnosed WNV disease. An initial estimation of
      efficacy will also be made.

      This Phase I/II study will enroll hospitalized adults with a presumptive diagnosis of West
      Nile encephalitis and/or myelitis or those with a positive laboratory test for diagnosis of
      WNV infection who are at high risk for progressing to severe neurologic disease based on age
      or immunosuppression. Patients will be randomized in blocks of five to receive either
      Omr-IgG-am(Trademark), Polygam(Registered Trademark) S/D (IVIG containing minimal anti-WNV
      antibodies) or normal saline in a ratio of 3:1:1. Patients and investigators will be blinded
      to treatment assignments.

      Patients will receive a single intravenous dose of study medication or one of two placebos.
      The study participants will receive 0.5 grams/kg of Omr-IgG-am(Trademark) or
      Polygam(Registered Trademark) S/D or a comparable volume of normal saline. All patients will
      be followed for safety, natural history endpoints, and efficacy. A subset of patients will
      have pharmacokinetic measurements of specific anti- WNV antibodies assessed following
      treatment.

      The primary endpoints are safety and tolerability following Omr-IgG-am(Trademark)
      administration.

      Secondary endpoints include pharmacokinetics of specific anti-WNV antibodies, mortality in
      confirmed WNV positive patients, and the combination of mortality and functional status at
      three months in both confirmed WNV-infected patients and all patients by intention to treat.
      This combined endpoint will be measured using four standardized measures of cognitive and
      functional status: the Barthel Index; the Modified Rankin Scale; the Glasgow Outcome Score;
      and the Modified Mini-Mental Status Examination. A comparison of outcomes will be made for
      the group receiving Omr-IgG-am(Trademark) versus those receiving either placebo, and between
      the two placebo groups. Other secondary endpoints include the proportion of patients in each
      group returning to pre-morbid baseline and each subject's improvement at 3 months as compared
      to that subject's worst (of any previous) evaluation.

      Natural history endpoints will also be assessed. They will include the duration of intensive
      care unit (ICU) and hospital stay, development and persistence of WNV-specific IgG and IgM
      antibodies, combined functional score and mortality at 3 months between the group with
      encephalitis and/or myelitis at baseline versus the group with a positive WNV test only,
      outcomes in patients treated late in coma and correlation of outcome with time-to-treatment
      following symptom onset.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators will assess whether Omr-IgG-am(Trademark), an intravenous immunoglobulin (IVIg)
      containing antibodies specific for West Nile virus (WNV), is safe and well-tolerated in
      patients with suspected or laboratory diagnosed WNV disease. An initial estimation of
      efficacy will also be made.

      This Phase I/II study will enroll hospitalized adults with a presumptive diagnosis of West
      Nile encephalitis and/or myelitis or those with a positive laboratory test for diagnosis of
      WNV infection who are at high risk for progressing to severe neurologic disease based on age
      or immunosuppression. Patients will be randomized in blocks of five to receive either
      Omr-IgG-am(Trademark), Polygam(Registered Trademark) S/D (IVIG containing minimal anti-WNV
      antibodies) or normal saline in a ratio of 3:1:1. Patients and investigators will be blinded
      to treatment assignments.

      Patients will receive a single intravenous dose of study medication or one of two placebos.
      The study participants will receive 0.5 grams/kg of Omr-IgG-am(Trademark) or
      Polygam(Registered Trademark) S/D or a comparable volume of normal saline. All patients will
      be followed for safety, natural history endpoints, and efficacy. A subset of patients will
      have pharmacokinetic measurements of specific anti- WNV antibodies assessed following
      treatment.

      The primary endpoints are safety and tolerability following Omr-IgG-am(Trademark)
      administration.

      Secondary endpoints include pharmacokinetics of specific anti-WNV antibodies, mortality in
      confirmed WNV positive patients, and the combination of mortality and functional status at
      three months in both confirmed WNV-infected patients and all patients by intention to treat.
      This combined endpoint will be measured using four standardized measures of cognitive and
      functional status: the Barthel Index; the Modified Rankin Scale; the Glasgow Outcome Score;
      and the Modified Mini-Mental Status Examination. A comparison of outcomes will be made for
      the group receiving Omr-IgG-am(Trademark) versus those receiving either placebo, and between
      the two placebo groups. Other secondary endpoints include the proportion of patients in each
      group returning to pre-morbid baseline and each subject's improvement at 3 months as compared
      to that subject's worst (of any previous) evaluation.

      Natural history endpoints will also be assessed. They will include the duration of intensive
      care unit (ICU) and hospital stay, development and persistence of WNV-specific IgG and IgM
      antibodies, combined functional score and mortality at 3 months between the group with
      encephalitis and/or myelitis at baseline versus the group with a positive WNV test only,
      outcomes in patients treated late in coma and correlation of outcome with time-to-treatment
      following symptom onset.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 22, 2003</start_date>
  <completion_date type="Actual">June 27, 2007</completion_date>
  <primary_completion_date type="Actual">June 27, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Actual">2</enrollment>
  <condition>West Nile Virus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omr-IgG-am</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        In order to participate in this clinical trial, all subjects (or legal representative) must
        provide written informed consent. Only patients meeting entry criteria will be enrolled.
        Eligible subjects must fall into one of two categories:

        A. Hospitalized patients greater than or equal to 18 years of age with encephalitis and/or
        myelitis as defined below:

        New neurologic abnormality:

        Asymmetric extremity weakness without sensory abnormality; or

        Other neurologic abnormality (including altered level of consciousness, dysarthria and
        dysphagia) plus fever (subjective or objective) within the previous 4 days

        AND

        CSF examination within the previous 96 hours showing:

        Absence of organism on gram or fungal stain

        White blood cell count greater than or equal to 4 per mm(3) corrected for significant red
        blood cell contamination.

        Ratio of CSF: plasma glucose of greater than or equal to 40% (CSF glucose/plasma glucose
        greater than or equal to 0.4)

        OR

        B. Hospitalized patients without encephalitis and/or myelitis as defined below who meet the
        following criteria:

        A positive IgM serology or PCR test for WNV in blood or cerebrospinal fluid,

        AND

        Clinical illness compatible with WNV infection as described by occurrence of greater than
        or equal to 3 of the following findings during the preceding less than or equal to 10 days:

        Diarrhea, headache, fever greater than 38 degrees Celsius, nausea and/or vomiting, myalgias
        and/or arthralgias, nuchal rigidity, macular or papular rash, new neurological abnormality

        AND

        A risk factor for the development of WNV neurologic disease as defined by:

        Age greater than or equal to 40 years, or

        Age greater than or equal to 18 years, plus immunosuppression, as defined by any of the
        following:

        Hematologic malignancy, previous diagnosis of diabetes mellitus, chemotherapy within
        previous 4 weeks, stem cell transplant recipient or solid organ transplant recipient,
        taking immunosuppressive medications, including prednisone greater than or equal to 7.5
        mg/day within the previous 4 weeks, history of human immunodeficiency virus (HIV)
        infection, congenital immunodeficiency syndrome (including common variable
        immunodeficiency)

        EXCLUSION CRITERIA:

        Unable to obtain valid informed consent

        History of intolerance (including anaphylaxis) to IVIg or related compounds

        Known history of IgA deficiency

        Known history of hypersensitivity to maltose.

        History of (or at time of study entry) hyperviscosity syndrome including but not limited
        to:

        Waldenstrom's macroglobulinemia

        Multiple myeloma

        Total white blood cell count greater than 80,000/mm(3)

        Hematocrit greater than 55%

        Platelet count greater than 700,000/mm(3)

        Meets criteria of Class III or IV of the New York Heart Association Classification for
        congestive heart failure patients

        Serum creatinine greater than 2.5 mg/dL or requires dialysis

        Alternate explanation (as determined by the investigator) for clinical findings (such as
        structural brain lesion, cerebrovascular accident, or other infectious disease, including
        confirmed infections with other flaviviruses)

        Pregnant or breastfeeding (negative serum or urine pregnancy test within previous 72 hours
        if woman is not postmenopausal or has not been surgically sterilized)

        Investigator's opinion that patient would be unable to adhere to protocol requirements

        Receipt of ribavirin, interferon alpha, intravenous immunoglobulin or any investigational
        drug for treatment of WNV or hepatitis within 15 days prior to study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988 May;19(5):604-7.</citation>
    <PMID>3363593</PMID>
  </reference>
  <reference>
    <citation>Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975 Mar 1;1(7905):480-4.</citation>
    <PMID>46957</PMID>
  </reference>
  <reference>
    <citation>McDowell I, Kristjansson B, Hill GB, HÃ©bert R. Community screening for dementia: the Mini Mental State Exam (MMSE) and Modified Mini-Mental State Exam (3MS) compared. J Clin Epidemiol. 1997 Apr;50(4):377-83.</citation>
    <PMID>9179095</PMID>
  </reference>
  <verification_date>February 18, 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2003</study_first_submitted>
  <study_first_submitted_qc>September 22, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2003</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <name_title>NIAID, DMID</name_title>
  </responsible_party>
  <keyword>West Nile Virus</keyword>
  <keyword>Encephalitis</keyword>
  <keyword>Virus</keyword>
  <keyword>Mosquito</keyword>
  <keyword>Fever</keyword>
  <keyword>WNV</keyword>
  <keyword>Myelitis</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

